Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (271-280 of 426) with videos related to

Pageof 43
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
Radiology|March 17, 2017
Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR ImagingJessica M Winfield, Nina Tunariu, Mihaela Rata, et al.
Future Oncology (London, England)|February 5, 2014
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancerL Rhoda Molife, Aurelius Omlin, Rob J Jones, et al.
The Oncologist|September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety AnalysesNiven Mehra, Karim Fizazi, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2018
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN LossJohann S de Bono, Ugo De Giorgi, Daniel Nava Rodrigues, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerGerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
Oncogene|January 10, 2017
Analysis of DNA methylation in single circulating tumor cellsC F Pixberg, K Raba, F Müller, et al.
Frontiers in Oncology|January 8, 2024
27-hydroxycholesterol and DNA damage repair: implication in prostate cancerGloria Cecilia Galvan, Nadine A Friedrich, Sanjay Das, et al.
European Urology|March 12, 2016
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate CancerPasquale Rescigno, David Lorente, Diletta Bianchini, et al.
Elife|September 17, 2015
SPOP mutation leads to genomic instability in prostate cancerGunther Boysen, Christopher E Barbieri, Davide Prandi, et al.
Pageof 43

Showing results (271-280 of 426) with videos related to

Sort By:
Pageof 43
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
Radiology|March 17, 2017
Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR ImagingJessica M Winfield, Nina Tunariu, Mihaela Rata, et al.
Future Oncology (London, England)|February 5, 2014
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancerL Rhoda Molife, Aurelius Omlin, Rob J Jones, et al.
The Oncologist|September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety AnalysesNiven Mehra, Karim Fizazi, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2018
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN LossJohann S de Bono, Ugo De Giorgi, Daniel Nava Rodrigues, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerGerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
Oncogene|January 10, 2017
Analysis of DNA methylation in single circulating tumor cellsC F Pixberg, K Raba, F Müller, et al.
Frontiers in Oncology|January 8, 2024
27-hydroxycholesterol and DNA damage repair: implication in prostate cancerGloria Cecilia Galvan, Nadine A Friedrich, Sanjay Das, et al.
European Urology|March 12, 2016
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate CancerPasquale Rescigno, David Lorente, Diletta Bianchini, et al.
Elife|September 17, 2015
SPOP mutation leads to genomic instability in prostate cancerGunther Boysen, Christopher E Barbieri, Davide Prandi, et al.
Pageof 43